Australian Clinical Labs to partner with Garvan and grow clinical genomics capability

Australian Clinical Labs and Garvan have reached an agreement to form a new partnership focused on growing clinical genomic capabilities and increasing community access that drives the development of precision medicine in Australia.
Media Release: 30 November 2018

Genome.One was established by the Garvan Institute in 2016 as the first clinically accredited whole genome sequencing service in Australia. Clinical Labs will now take on responsibility for its clinical pathology and reporting services, working closely with the Garvan Institute, where all whole genome sequencing will continue.

Unlocking the secrets of inherited disease through advanced research has driven decades of scientific enquiry and captured the imagination of the medical and commercial investment communities. Genomics has uncovered medical discoveries around cancer, heart conditions and numbers of rare diseases. Advanced genomics has potential to shift healthcare from a one size fits all treatment regime to one that offers patients precise treatments based on tests that identify variations in the DNA in an individual’s genome. 

“Clinical Labs has two leading clinical molecular genetic services, one in Victoria and the other in Western Australia. We work closely with medical practitioners to deliver precise diagnostics and personalised treatment plans, based on a patient’s genetic makeup. We have long been leaders in clinical molecular genetics in the fields of cancer, mental health, sexual health, pregnancy, genetic screening, blood disorders and drug therapy.

“Genome.One’s genome pathology service team will become part of Clinical Labs and remain located in Sydney at the Garvan Institute. Our molecular genetics team will work closely with the Garvan researchers and their sequencing team to build a bigger and more advanced precision medicine pathology service. In combination, our work will advance the translation of genomics research into clinical practice and improve our diagnostic pathology service by taking clinical learnings back to the researchers,” said Group CEO and Managing Director at Clinical Labs, Melinda McGrath.

Executive Director of the Garvan Institute, Professor Chris Goodnow welcomes the partnership with Clinical Labs. “The Garvan Institute is a pioneer in developing genomics and the application of genomics in Australia. This new partnership continues and grows the translation of Garvan’s genome sequencing and analysis capabilities as a critical diagnostic service, serving doctors and families across Australia. Drawing upon the very best research, this service has already changed young lives and transformed the care of many Australians. It is now set to do even more,” he said.

Members of the Genome.One group joined Clinical Labs on Monday 26th November 2018.

(ENDS)

 

Media Inquiries for GIMR:

Anna Sweeney

+61 (0)437 282 467 

+ 61 (0)2 9295 8126

a.sweeney@garvan.org.au

www.garvan.org.au

 

Media Inquiries for Australian Clinical Labs:

Justine Larkins

+61 (0) 421 883 766

+61 (3) 9538 6766

justine.larkins@clinicallabs.com.au

www.clinicallabs.com.au

 


About Australian Clinical Labs

Australian Clinical Labs combine pathology leadership, ground-breaking technology and the best scientists in the field to bring better outcomes for doctors and patients alike.

Clinical Labs is the largest pathology provider to public hospitals in Australia and one of the top choices amongst private practices across the country. With over 90 NATA accredited laboratories and 900 collection sites nation-wide, the company performs around 8 million episodes a year for a range of clients including doctors, specialists, patients, hospitals and corporate clients.

Clinical Labs is a leader in molecular testing and new technologies and employs over 3,800 employees including more than 90 highly respected and experienced pathologists.  https://www.clinicallabs.com.au/

About Garvan

The Garvan Institute of Medical Research is one of Australia's largest medical research institutions and is at the forefront of next-generation genomic sequencing in Australia.

Garvan’s main research areas are: cancer, diabetes and metabolism, genomics and epigenetics, immunology and inflammation, osteoporosis and bone biology, and neuroscience.

Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health.